The following elements will have their visibility changed, please review the list before confirming the visibility change

Study

Study Name: Plasmodium vivax PvW1 genome

Projects

Biosamples

Organisms

Biosamples: 0 Seq. Projects: 1
STUDY INFORMATION
GOLD Study ID Gs0156691
Study Name Plasmodium vivax PvW1 genome
Other Names
NCBI Umbrella Bioproject Name
NCBI Umbrella Bioproject Accession
SRA Studies
SRA Study Id ERP129582  (Link to NCBI )
Study Title Controlled_human_malaria_infection_with_PvW1___a_new_clone_of_Plasmodium_vivax_with_high_quality_genome_assembly
Study Abstract Abstract BACKGROUND: Controlled human malaria infection (CHMI) provides a highly informative means to investigate host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new drugs and vaccines. However, unlike Plasmodium falciparum, the P. vivax parasite cannot be cultured long-term in vitro, meaning stocks of well-characterized parasites that are safe and suitable for use in modern CHMI models have been limiting. METHODS and FINDINGS: Two healthy malaria-naïve UK adults with universal donor blood group were safely infected with a clone of P. vivax from Thailand by mosquito-bite CHMI. Parasitemia, but minimal gametocytemia, developed in both volunteers and treatment successfully cleared the infection with no documented relapse. Prior to treatment, each volunteer donated blood to produce a cryopreserved stabilate of infected red blood cells. Following stringent safety screening, the parasite stabilate from one of these donors (which we called “PvW1”) was thawed and used to inoculate six healthy malaria-naïve UK adults by blood-stage CHMI. Three different dilutions of blood-stage inoculum were used (n=2 per dose). Parasitemia and gametocytemia developed in all six volunteers, who were then successfully drug treated. The adverse event profiles of mosquito-bite and blood-stage CHMI were comparable, with malaria symptoms resolving within a few days of treatment, however notable differences in gametocytemia and the blood-stage parasite multiplication rate were observed between the two human infection models. PvW1 parasite DNA was isolated and sequenced to produce a high quality genome assembly by using a hybrid assembly method which combined long PacBio reads with short Illumina reads. We analysed leading vaccine candidate antigens and multigene families, including the Vivax interspersed repeat (VIR) genes of which we identified 1145 in the PvW1 genome. CONCLUSIONS: We have demonstrated the safety and feasibility of mosquito-bite and blood-stage CHMI using the same PvW1 clone of P. vivax. Our genomic analysis will guide future assessment of candidate vaccines and drugs, as well as experimental medicine studies. The PvW1 parasite should prove to be an invaluable resource for the wider malaria community. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03377296 and NCT03797989. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
  
Legacy ER Study ID
Legacy GOLD ID
Added By JGI automated process on 2022-03-02
Last Modified By
PI
Description Plasmodium vivax PvW1 genome
Relevance
Study Information Visibility Public
Metagenomic Study No
Publication
Is GEBA
Is HMP
ECOSYSTEM CLASSIFICATION
Ecosystem
Ecosystem Category
Ecosystem Type
Ecosystem Subtype
Specific Ecosystem
Ecosystem Path ID 1
STUDY COMPOSITION
Number of Biosamples 0
Number of Organisms 1
Number of Seq Projects 1
Number of Analysis Projects 1
Number of Related Studies 0

 

 

  You are going to add the following user to ALL Sequencing Projects, Biosamples and Analysis Projects that
sit under this study (a cascading permission update).

 

Contact Name/Email:

Do you want to continue?

 

 

  You are going to remove permissions for the following user to all Sequencing Projects,
Biosamples and Analysis Projects under this study.

 

Contact Name/Email:

Do you want to continue?